OriBase Pharma is the result of the merger between Nova Decision and Azasynth. Before the merger in 2010, our services were recognized through the French Ministry of Research and technology.
Prior to the creation of OriBase Pharma, Nova Decision and Azasynth both won the National Competition for Aid to Business Creation of Innovative Technologies; Nova Decision in 2007 and 2008, Azasynth in 2007.
This competition is organized annually by the French Ministry of Research and Technology, whose objective is to detect, select, and help emerging companies who develop innovative technologies.
Through these awards, Nova Deicison & Azasynth obtained financing to support 3 years of R&D in creating their own technology platform, HitFast Discovery®, and the proof of concept for identifying and optimizing novel, potent, and selective kinase inhibitors involved in oncology.
Learn more about HitFast Discovery®.